All News

The use of multiple medications is associated with increased severity of erectile dysfunction, say researchers from Kaiser Permanente Los Angeles Medical Center.

Dendreon Corp. has announced that the Centers for Medicare & Medicaid Services has updated its coverage policy to now cover the infusion costs associated with the administration of the advanced prostate cancer immunotherapy sipuleucel-T (Provenge).

Treatment with the RANK ligand inhibitor denosumab (XGEVA) is effective at delaying the development of bone metastases in men with nonmetastatic castration-resistant prostate cancer, according to a recent multicenter study.

An international research team has discovered a genetic Achilles' heel in neuroendocrine prostate cancer-a vulnerability that researchers say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.

Pacific Urology and Diablo Valley Oncology and Hematology Medical Group, both located in Contra Costa County in California, are merging to form a 13-physician group.

Kidney transplants performed using organs from live donors over the age of 70 years are safe for both donors and recipients, according to a recent study.

Prostate cancer patients who undergo radical prostatectomy achieve better results at teaching hospitals than at non-academic medical institutions, according to the findings of an international study led by researchers at Henry Ford Hospital?s Vattikuti Urology Institute, Detroit.

Aristolochic acid, a plant component used in herbal remedies, appears to lead to kidney failure and urothelial cell carcinomas (UCC) in individuals exposed to the toxin, an international group of researchers reports.

Glenn M. Preminger, MD, has been appointed chief of urologic surgery at Duke University Medical Center, Durham, NC.

Men who take a daily vitamin E supplement face an increased risk of prostate cancer, according to a new report summarizing the latest results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

The Alliance of Specialty Medicine soundly rejected MedPAC?s approval of a recommendation that Congress reform the Medicare reimbursement system by reducing reimbursements to specialists by 5.9% per year for 3 years while freezing the reimbursement rate for primary care physicians.

Efforts in an increasing number of states to not provide Medicaid insurance coverage for male circumcision, as well as an attempted ballot initiative in San Francisco earlier this year to ban male circumcision in newborns and young boys, are unwarranted, say infectious disease experts from Johns Hopkins University, Baltimore.

Researchers at Fred Hutchinson Cancer Research Center and the University of Washington, Seattle have discovered a number of potential key drivers?recurrent genetic mistakes?common to advanced prostate cancer that may contribute to disease progression.

Men over 75 years of age are being undertreated for prostate cancer, while patients with a single comorbid condition such as peripheral vascular disease are being overtreated and doing much more poorly than expected, say researchers from UCLA?s Jonsson Comprehensive Cancer Center.

The future of patient-centered urologic care depends on collaboration with allied advocacy affiliates.

This list of National Institutes of Health trials is derived from the NIH's database and includes phase III and IV bladder cancer trials and phase II overactive bladder trials. This list is current as of Sept. 15, 2011.

Near infrared fluorescence imaging of intravenous indocyanine green during robot-assisted laparoscopic partial nephrectomy can accurately identify the renal vasculature and successfully differentiate tumor from surrounding parenchyma.

Serum testosterone concentration rises in a predictable manner after implantation of extended-release testosterone pellets (Testopel), and the dose response is not impacted by the patient's body mass index.

Accumulating data from patients with progressive, castration-resistant prostate cancer enrolled in a phase I-II study of MDV3100 show this novel antiandrogen has durable antitumor activity in both pre- and post-chemotherapy populations.

An investigational minimally invasive urethral expansion system achieved significant and durable improvement in BPH/lower urinary tract symptoms in a multicenter study.

By analyzing work relative value units (RVUs) in a number of urology groups, we have verified that they have had an approximate 10% decrease in income while generating the same number of work RVUs.

The newest urology products and services from US Urology, Cook Medical, Abbott Laboratories, the Medical Collaboration Network, the Agency for Healthcare Research and Quality, the AUA Foundation, and Trophikos, LLC.

A team at the University of Washington School of Medicine and Applied Physics Lab, Seattle, is refining prototype technology that should allow extracorporeal ultrasound to image and, more importantly, move stones in a kidney as if they were being nudged gently by a pool cue.

Those of us who are not employed by a hospital or other entity remain small business men/women, and therefore need to be as attentive to the business aspect of our practices as we are to the clinical care we offer our patients.

Repeat injections of onabotulinumtoxinA (Botox) over the long term are showing value in patients with interstitial cystitis.

The investigational selective beta3-adrenoceptor agonist mirabegron effectively improves symptoms of overactive bladder and is very safe and well tolerated.